Dr. Myrdal has 20+ years of pre-formulation and formulation experience. His experience ranges from preclinical biological interactions, to scale up and validation of manufacturing processes, to Chemistry, Manufacturing, and Control (CMC) preparation for Investigational New Drug (IND) applications.
Prior to joining the University of Arizona College of Pharmacy, Dr. Myrdal was employed by 3M Drug Delivery, where he was a key investigator in the development and formulation of topical AldaraTM (indicated for the treatment of basal cell carcinoma) as well as Qvar HFATM (an inhalation product for treatment of asthma).
During his sixteen years at the University of Arizona, one of Dr. Myrdal's primary areas of interest has been formulating poorly soluble and/or unstable anticancer drugs with an emphasis on topical and inhalation delivery. As such, he has had numerous opportunities to collaborate with the University of Arizona Cancer Center (UACC). He has been the Director of the Drug Development Core for the Skin Cancer Program Project Grant for eight years, which has allowed him to work closely with other members of UACC. Also, as a member, he has been able to utilize several services and cores provided by UACC for other research endeavors focused on skin and lung cancer. These include the Analytical Chemistry and the Experimental Mouse Shared Resources.